biotherapeutics News
-
Axial Biotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that management will present at the H.C. Wainwright Annual Global Investment Conference on Tuesday, September 15, 2020 at 2:00 PM ET. About Axial Biotherapeutics Axial Biotherapeutics is a clinical stage ...
-
20th Annual Biotech in Europe Forum for global partnering & investments
MV BioTherapeutics is participating at this important annual event and virtually meet potential investors and licensing partners. Please contact us for a personal meeting within the partnering system or outside it. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in ...
-
Bio International Convention Digital June 8-12, 2020
Thanks to the support of Innosuisse, MV BioTherapeutics is participation at this important annual event within the Swiss Pavillon hosted and supported electronically by the Switzerland Global Enteprise (https://www.s-ge.com/en/sbh) . We look forward meeting potential investors and licensing partners. About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome ...
-
MV BioTherapeutics to present at the 6th Microbiome Movement - Drug Development Europe
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 6thMicrobiome Movement – Drug Development Summit Europe 2022 in London during January 25th-27th, 2022. The presentation has been included in stream A titled “Understanding mechanisms of action & preclinical development” the 26th at 13.45. Microbiota Adaptation ...
-
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
New York, New York, March 22, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that Alan Horsager, Ph.D., President and Chief Executive Officer of Duet BioTherapeutics, will present at the 3rd Annual STING & TLR-Targeting ...
-
New company name and website
We are proud to announce the launch of the company website that provides most relevant information on the technology and pipeline of MV BioTherapeutics. We have changed the original name of the company from MicroVaccines to MV BioTherapeutics (from now on MV). “During the past years we have developed therapeutic live biotherapeutics with different mode of action as compared to the original ...
-
You`re invited to our webinar `How to Screen Binding Kinetics in 3 Easy Steps with the New EzPlex System`.
During this webinar you will learn how the new features of the fully-automated EzPlex system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular ...
-
Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
New York, New York, October 18, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today the completion of a series of related recapitalization transactions designed to enhance shareholder value. These transactions include the elimination of ...
-
You`re invited to our webinar `How to Screen Binding Kinetics in 3 Easy Steps with the New EzPlex System`.
During this webinar you will learn how the new features of the fully-automated EzPlex system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular ...
-
Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis.
Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis. During this webinar you will learn how the new features of the fully-automated XelPleX system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ...
-
BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates
BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that it has entered into a long-term lease for a new facility in Sunnyvale, California. This facility is being built out to support the manufacturing of BioCardia’s cell and device products and product candidates across the ...
-
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
New York, New York, November 10, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and ...
-
MV BioTherapeutics to present at 5th Microbiome Movement - Drug Development Europe
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 5th Microbiome Movement – Drug Development Summit Europe 2021 being held virtually during January 27th-29th, 2021. The presentation has been included in the morning stream titled “Introducing the Era of Engineered Microbes” the 29th at 11.35. Leveraging Gut Microbiota ...
-
Chrysalis BioTherapeutics Granted Orphan Drug Status for TP508
Chrysalis BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) Office of Orphan Product Development and the European Medicines Agency (EMA) have granted Orphan Drug Designation (ODD) to the company’s lead compound, TP508 (rusalatide acetate) for the treatment of acute radiation syndrome (ARS). With exposure to high levels of nuclear radiation, individuals ...
-
Axial Biotherapeutics Announces a Research Grant Award from The Michael J. Fox Foundation for the Development of an Enteric Nervous System Model to Assess Novel Parkinson’s Disease Therapeutics
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announces it has received a research grant of $440,000 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutic Pipeline Program. The award will enable development of a novel ...
-
Chrysalis Biotherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases (NIH-NIAID) to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear detonation. “TP508 represents a natural product released at sites of tissue injury to ...
-
Notitia Biotechnologies Develops Revolutionary Foundation Guild Lbp for Patients With Diabetic Kidney Disease (DKD)
Notitia Biotechnologies Company has developed a ground-breaking live biotherapeutic product (LBP) for patients with early-stage and end-stage diabetic kidney disease (DKD) patients. The drug, NBT-BM306, combines the purified Foundation Guild bacteria and the tailored microbiome nutrition to support their growth in one convenient format. Notitia is preparing the Investigational New Drug (IND) ...
-
MV Biotherapeutics and Malcisbo agree to explore the Apyrase technology platform for AH Vaccines
MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant. Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the exclusive right to use MV Bio ...
-
DermBiont Announces Positive Results from Phase 2b Clinical Trial in Tinea Pedis
BOSTON, Jan. 8, 2021 /PRNewswire-PRWeb/ -- DermBiont, a clinical-stage biotechnology company developing targeted topical therapeutics, announced today that its phase 2b clinical trial with its investigational drug product, DBI-001, for the treatment of tinea pedis resulted in statistically significant decreases in the abundance in T. rubrum, statistically significant improvement in the ...
-
Meet us at PDA 2022
2022 PDA : the Scientific Program Planning Committee and the PDA have joined forces with the Lyophilization Conference to provide a comprehensive experience that includes all emerging trends in biomanufacturing. In this context, Indatech teams will be present at the 2022 PDA BioManufacturing Conference with great demonstrations of NIR Hyperspectral and UV VIS! The health emergency has ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you